-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Assembly Biosciences, Raises Price Target to $43

Benzinga·04/06/2026 11:56:51
Listen to the news
Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $39 to $43.